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able organic carbon level, degree of pipe corrosion, and
treatment/distribution system characteristics. Chloramine is
considerably more effective than chlorine for controlling
Legionella in biofilms, presumably because chloramine is
more stable and thus less reactive than chlorine, allowing it to
penetrate the biofilm more deeply.
An important factor in distribution system contamina-
tion and bacterial growth on biofilms is transient water
pressure fluctuations that create pressure waves that pass
through pipes in the distibution system. During the negative
portion of the pressure wave, a substantial amount of
contaminated water (>1 gal per minute) from the outside can
be pulled into pipes through a small leak. This problem is
aggravated when sewer lines are placed close to water pipes.
Dr. LeChevallier stated that a number of waterborne disease
outbreaks have been linked to distribution system
deficiencies. Among the agents of nosocomial waterborne
disease is MAC. This opportunistic bacterial pathogen lives in
water, is resistant to water disinfection (much more so than
Giardia cysts), and grows in pipe biofilms.
During transitional periods new scientific understand-
ings bring new questions. The pivotal issues in xenotrans-
plantation concern biohazards. The U.S. Public Health
Service defines xenotransplantation as “. . . any procedure
that involves the transplantation, implantation, or infusion
into a human recipient of either A) live cells, tissues, or organs
from a nonhuman animal source or B) human body fluids,
cells, tissues, or organs that have had ex vivo contact with live
nonhuman animal cells, tissues, or organs.”
Prior to 1990, xenotransplants were largely whole organs;
recipients survived only days or weeks. However, in most
recent xenotransplantation trials, immunoprotected porcine
neurologic, pancreatic, and hepatic cells are used to treat
degenerative neurologic disorders, diabetes, or hepatic failure.
Increasingly, xenotransplantation products function for
prolonged periods in recipients who survive months or years.
Xenotransplantation is a public health concern because it
has the potential to infect human recipients with agents that
do not ordinarily infect humans, thereby introducing new
infections to humans. Therefore, xenotransplantation
combines a potential benefit with a potential risk to humans
that is presently unknown.
Xenogeneic infections belong to a larger category of
“bioproduct-acquired” infections, an example of which is
simian virus 40 (SV40). SV40, a polyomavirus, contaminated
polio vaccine stocks in the 1950s. Investigations into whether
SV40 infection is associated with an increased risk of cancer
have been inconclusive. This lingering uncertainty about the
long-term significance of apparently innocuous persistent
human infection with nonhuman viruses underscores the
potential for therapeutic use of bioproducts to have
unintended consequences.
The PHS Guideline on Infectious Disease Issues in
Xenotransplantation describes a system of safeguards built
around two key concepts: pretransplant screening of some
animal herds, source animals, and xenotransplantation
products to minimize the risk of xenogeneic infections with
recognized pathogens and posttransplant surveillance of
recipients for previously unrecognized xenogeneic organisms.
Endogenous retroviruses exist as inactive proviral DNA
in the germline of all mammals adequately studied to date.
However, inactive genomic endogenous retroviruses can often
express active virus capable of infecting human cell lines in
vitro. Thus, xenotransplantation products contain benign
genomic DNA that, on transfer into a human, may express
infectious retrovirus capable of creating active, persistent
infection. The importance of this infectious potential of
animal tissue devoid of any identifiable exogenous
microorganisms has been the subject of much concern and
scientific inquiry over the past 5 years.
To date, limited studies on humans exposed to pig cells
and tissues have produced no evidence of porcine endogenous
retrovirus infection. However, the persistent presence of
microchimeric xenogeneic pig cells in the human recipient
confirms that even temporary exposure to xenotransplanta-
tion products may continuously expose humans to infectious
agents contained within them. For this reason, it is argued
that humans should not be exposed to xenotransplantation
products containing infectious agents whose ability to infect,
cause disease in, or be spread among humans is incompletely
defined.
Xenotransplantation is a process that occurs under
controlled circumstances; thus, measures can be implement-
ed to minimize associated iatrogenic biohazards. Studies
performed in the service of developing policies on
xenotransplantation can model other approaches to science-
based risk minimization used for other bioproducts.
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